

AMENDMENTS TO THE SPECIFICATION

Please replace the current abstract with the following amended abstract.

The present invention relates to a medicament comprising a HGF gene method for treating insufficiency of peripheral circulation or peripheral angiostenosis in a subject for which HGF is effective, comprising administering to the area affected by the insufficiency of peripheral circulation or peripheral angiostenosis a therapeutically effective amount of an expression vector containing a constitutive promoter operably linked to a HGF coding sequence, whereby the HGF is expressed, promoting the growth of vascular endothelial cells but not vascular smooth muscle cells. The medicament of the present invention may be topically applied to the target organs so that the effects can be selectively inhibited, resulting in minimizing the side effects of HGF.